Allurion shares fall 10.68% intraday after NYSE delisting notice due to non-compliance with financial thresholds.

Allurion Technologies (ALUR) fell 10.68% intraday following news that the New York Stock Exchange (NYSE) intends to initiate delisting proceedings due to the company’s failure to meet continued listing standards, specifically maintaining at least $50 million in stockholders’ equity or market capitalization. The NYSE determined Allurion had not regained compliance by the end of its grace period, triggering the delisting process. While the company announced plans to appeal and highlighted recent FDA approval as a catalyst for regaining compliance, the immediate delisting threat signaled financial instability and raised concerns about liquidity and long-term viability. Allurion’s efforts to restructure, including debt exchanges and capital-raising initiatives, were not sufficient to offset the negative market reaction to the delisting notice, which underscores significant regulatory and operational risks.